Internal Medicine, Hematology & Oncology · Lubbock, TX
NPI
1790944056
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4101 22nd Pl
Lubbock, TX, 79410
Phone (806) 725-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
2,556 services
Medicare patients, 2024
490
Average age 75
Drug cost, 2024
$7.1M
3,244 prescriptions
Company payments, 2025
$273
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kiran K Yalamanchili was code 99214 (office e&m - established), 950 times for 220 patients. In total Kiran K Yalamanchili billed 2,556 services in 19 codes, and Medicare paid $133K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 950 | 220 | $68.93 | $65K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 605 | 278 | $12.47 | $7,545 |
| 99213 Office E&M - Established | Facility | 379 | 238 | $42.79 | $16K |
| 99232 Hospital E&M - Subsequent | Facility | 282 | 88 | $59.42 | $17K |
| 99233 Hospital E&M - Subsequent | Facility | 63 | 18 | $89.88 | $5,663 |
| 99222 Hospital E&M - Initial | Facility | 59 | 51 | $98.83 | $5,831 |
| 99238 Hospital Discharge Management | Facility | 52 | 35 | $61.23 | $3,184 |
| 99204 Office E&M - New | Facility | 50 | 50 | $96.74 | $4,837 |
| 99203 Office E&M - New | Facility | 47 | 47 | $59.07 | $2,776 |
| 99223 Hospital E&M - Initial | Facility | 28 | 18 | $126.48 | $3,541 |
By year: 2022 $102K for 1,638 services; 2023 $136K for 2,130 services; 2024 $133K for 2,556 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kiran K Yalamanchili prescribed most often to Medicare patients was Acyclovir, with 163 prescriptions and refills. In total Kiran K Yalamanchili wrote 3,244 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 163 | 236 | 35 | $2,119 |
| Eliquis Apixaban | 155 | 180 | 30 | $96K |
| Dexamethasone Generic | 149 | 171 | 48 | $1,625 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 124 | 124 | 36 | $2,818 |
| Prednisone Generic | 121 | 131 | 42 | $448 |
| Hydroxyurea Generic | 106 | 158 | 19 | $1,476 |
| Potassium Chloride Generic | 91 | 150 | 30 | $1,661 |
| Ondansetron Odt Ondansetron | 91 | 91 | 40 | $920 |
| Anastrozole Generic | 90 | 145 | 17 | $1,230 |
| Lenalidomide Generic | 84 | 84 | 13 | $1.3M |
| Gabapentin Generic | 74 | 94 | 20 | $610 |
| Levothyroxine Sodium Generic | 74 | 128 | 20 | $587 |
| Valacyclovir Valacyclovir Hcl | 74 | 94 | 16 | $1,513 |
| Prochlorperazine Maleate Generic | 65 | 65 | 37 | $432 |
| Tramadol Hcl Generic | 62 | 62 | 25 | $331 |
Brand drugs: - claims; generic drugs: 2,502 claims; opioid claims: 231.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kiran K Yalamanchili $273 ($273 in general payments such as food, travel and fees) from 10 companies. The largest payer was Janssen Biotech, Inc. with $56.44.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 3 | $56.44 |
| Abbvie Inc. ABBV | 2 | $36.11 |
| Merck Sharp & Dohme LLC MRK | 1 | $32.51 |
| Array Biopharma Inc PFE | 1 | $29.3 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $25.53 |
| Genentech USA, Inc. ROG.SW | 1 | $25.04 |
| Celgene Corporation BMY | 1 | $24.45 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $24.14 |
| Pfizer Inc. PFE | 1 | $19.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.